| Literature DB >> 28467435 |
Yu-Chi Chen1, Pin-Hsuan Lin2, Yann-Yuh Jou3, Victor Chia-Hsiang Lin1,4,5.
Abstract
BACKGROUND: This meta-analysis was designed to assess the efficacy of the male sling and artificial urinary sphincter on treating post-prostatectomy incontinence by evaluating daily pad use, cure rate, frequency of improvement in incontinence, and quality of life.Entities:
Mesh:
Year: 2017 PMID: 28467435 PMCID: PMC5415174 DOI: 10.1371/journal.pone.0130867
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Study selection flow chart.
Summary of basic characteristics and outcomes of selected studies for meta-analysis.
| Study number | 1at Author (year) | Number of patients | Age (years) | Duration of follow up (months) | Pad use (pads/ day) | Definition of cured rate | Cured rate (%) | Definition of improved rate | Improved rate (%) | QoL Instrument | QoL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Grise (2012) | 122 | 69.4 | NA | 2.4g. 0.6 | NA | NA | Decreases pad use | 87% | NA | NA |
| 2 | Leruth (2012) | 173 | 67.3 | 28 (12, 60) | NA | No pad use | 49% | Two or fewer pads and a reduction of pads ≥50% | 35% | Ditrovie quality of life | 32 (14) vs. 19 (10) |
| 3 | Rehder (2012) | 156 | 68 (63, 72) | 40.1 (6.0) | 4.0 (2, 6) | No pad or one dry pad for security reasons | 53.8% | One to two wet pads or a reduction of pads ≥50% | 23.1% | Incontinence Quality of Life | 61 (45, 71) |
| 4 | Bauer (2011) | 24 | 71 (62, 77) | 18.8 (12, 33) | NA | No pad or one dry pad for security reasons | 25% | One to two wet pads or a reduction of pads ≥50% | 25% | Incontinence Quality of Life | 52.5 (35, 67) |
| 5 | Ceresoli (2010) | 12 | 72 | 26 (24, 27) | NA | Complete response | 58.3% | Partial response | 33.3% | NA | NA |
| 6 | Cornel (2010) | 35 | 68.5 (55.0, 82.6) | NA | NA | NA | 9% | NA | 45.5% | NA | NA |
| 7 | Cornu (2010) | 136 | 67.4 (6.8) | 21 (6) | 2.1 (1.2) vs. 0.6 (1.0) | No pad usage | 62% | A decrease in pad use by > 50% | 16% | NA | NA |
| 8 | Soljanik (2010) | 35 | 68.4 (6.8) | 16.6 | 4.4 (3.0) vs. 0.9 (3.0) | No pad or one dry pad for security reasons | 72.4% | One to two wet pads or a bFreduction of pads ≥50% | 17.2% | Incontinence Quality of Life | 60.6 (16.9) vs. 88.3 (17.8) |
| 9 | Wadie (2010) | 40 | 66 (20, 80) | 24 | NA | Dry | 85% | NA | NA | NA | NA |
| 10 | Bauer (2009) | 124 | 68.9 (54, 87) | NA | 4 (3, 6)2 vs. 0 (0, 1) | No pad or one dry pad for security reasons | 51.4% | One to two wet pads or a reduction of pads ≥50% | 25.7% | Incontinence Quality of Life | 59.5 (47, 70) |
| 11 | Grise (2009) | 50 | 72 (64, 77) | NA | 2 (2, 3) | NA | NA | NA | NA | SF-36 | 100 (83, 133) |
| 12 | Guimarães (2009) | 62 | 69 (57, 78) | 28 | Stopped wearing continence pads | 63% | Reduction of pads ≥50% | 24% | NA | NA | |
| 13 | Gilling (2008) | 37 | 69.9 (59, 79) | 51.5 (24, 60) | 2.8 (2.1) vs. 0.8 (0.9) | NA | NA | NA | NA | Incontinence Quality of Life | 49.7 (19.3) vs. 81.4 (15.3) |
| 14 | Inci (2008) | 19 | 67.5 (59, 80) | 17.3 (12, 25) | 10.3 (2.5) vs. 0.6 (1.4) | Completely dry | 78.9% | Improved significantly to 1 to 2 pads per day | 10.5% | NA | NA |
| 15 | Fischer (2007) | 62 | 51 (45, 84) | 15 (3, 37) | NA | NA | NA | Determined by the Patient Global Impression of Improvement | 58% | NA | NA |
| 16 | Gallagher (2007) | 31 | 66 (54, 83) | 15 (9, 21) | 3.7 (1, 12) | Dry or using less than 1 pad/day | 75% | NA | NA | Male Urinary Symptom Impact Questionnaire | 29.9 (18.8) vs.14.6 (16.1) |
| 17 | Rehder (2007) | 20 | 65.3 (47, 81) | NA | 5.5 (5, 7) | No pad usage | 40% | One to two pads per day | 30% | NA | NA |
| 18 | Sousa-Escando´n (2007) | 51 | 69 (58, 81) | 32 (16, 50) | NA | No pads or small pads or sanitary napkins for security but normally remained dry | 64.7% | Important improvement | 19.6% | NA | NA |
| 19 | Wadie (2007) | 23 | 64.6 (8.9) | 9 (6, 24)3 | NA | Completely dry | 87% | Greatly improved | 20% | NA | NA |
| 20 | Romano (2006) | 48 | 67.7 (52, 77) | 7.5 (1, 17.5) | 5 (3, 8) | Dry | 73% | Mild, sporadic incontinence, one or fewer pads/day | 10% | Incontinence Questionnaire, Short-Form | 19.2 (12, 21) |
| 21 | Stern (2005) | 9 | 74 (59, 86) | 48 (3.2, 79) | NA | No pad | 11% | One to two pads | 56% | Incontinence Quality of Life questionnaires | 100% (4 responses having a minimal or mild impact on their lives on urinary symptoms |
| 22 | John (2004) | 19 | 67 (56, 83) | NA | 7 (2–12)1 vs.1 (0, 10) | No pad or one dry pad | 69% | Reduction of urine leakage or pads ≥50% | 6% | Quality of life of incontinent men | 6 (4, 6) |
| 23 | Schaal (2004) | 30 | 68 (50, 78) | 4 (2, 12) | NA | No need for pads | 67% | Requiring 1 to 2 pads daily | 13.3% | NA | NA |
| 24 | Comiter (2002) | 21 | 67 (32, 80) | 12 (5, 21) | NA | Leakage no problem, no pads | 76% | Leakage very small or small problem, 1 pad daily | 14% | NA | NA |
| 25 | Madjar (2001) | 16 | 67 (56, 74) | 12.2 (4, 20) | NA | No or 1 pad used daily for security without any episode of leakage | 75% | A decrease of 50% or more in pads daily | 12.5% | NA | NA |
| 26 | Jorion (1997) | 30 | 65 (53, 75) | NA | NA | No protection needed at any time | 98% | NA | NA | NA | NA |
| 1 | Lai (2011) | 129 | 69.0 (0.6) | 34.1 (2.7) | 5.2 (0.3) vs. 1.1 (0.1) | NA | NA | NA | NA | NA | NA |
| 2 | Hübner (2007) | 50 | 72 (62, 80)1 | NA | 6.3 (4.3) vs. 2.1 (2.1) | 0–1 security pad/d | 52% | a reduction of pads ≥50% | 8% | Incontinence Quality of Life | 33 (19.8) vs. 64 (24.7) |
| 3 | Kocjancic (2007) | 65 | 65.4 (25, 79) | 19.5 (12, 62) | 5.2 vs. 1.5 (3.0) | 0–1 safety pad/day | 67% | ≥2 pads/day but >50% pad reduction | 17% | Incontinence Quality of Life | 31.7 vs. 71.1 (23.9) |
| 4 | Trigo-Rocha (2006) | 25 | 68.6 (61, 72) | 22.4 (6, 48) | 4.8 (1.7) vs. 1.8 (1.6) | Using 0 to 1 pad daily and satisfied | 60% | Improved but unsatisfied | 12% | Incontinence Quality of Life | 63.0 (20.4) vs. 82.6 (12.2) |
| 5 | Imamoglu (2005) | 11 | 64 (52, 76) | NA | 1.33 vs. 0.09 | Dry | 90.9% | Socially continent | 9.1% | SEAPI QMM | 26.8 vs. 6.8 |
| 6 | Kuznetsov (2000) | 41 | NA | 19 | NA | No p | 29% | ≤1 pad/day | 37% | NA | NA |
| 7 | Mottet (1998) | 103 | NA | NA | NA | Dry | 57% | Social continence | 26% | NA | NA |
| 8 | Litwiller (1996) | 50 | 71 (51, 83) | 23.4 | NA | NA | NA | NA | 72% | NA | NA |
1mean (range).
2 median (IQR).
3 median (range).
NA, not available.
The summarized results of quality assessment for included studies.
| Study no. | 1st author (year) | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Is the hypothesis/aim/objective of the study clearly stated in the abstract, introduction, or methods section? | Are the characteristics of the participants included in the study described? | Were the cases collected in more than one centre? | Are the eligibility criteria (inclusion and exclusion criteria) to entry the study explicit and appropriate? | Were participants recruited consecutively? | Did participants enter the study at a similar point in the disease? | Was the intervention clearly described in the study? | Were additional interventions (co-interventions) clearly reported in the study? | Are the outcome measures clearly defined in the introduction or methods section? | Were relevant outcomes appropriately measured with objective and/or subjective methods? | Were outcomes measured before and after intervention? | Were the statistical tests used to assess the relevant outcomes appropriate? | Was the length of follow-up reported? | Was the loss to follow-up reported? | Does the study provide estimates of the random variability in the data analysis of relevant outcomes? | Are adverse events reported? | Are the conclusions of the study supported by results? | Are both competing interest and source of support for the study reported? | ||
| 1 | Grise (2012) | Y | Y | Y | Y | N | Y | Y | N | Y | Y | Y | N | Y | Y | Y | Y | Y | Y |
| 2 | Leruth (2012) | Y | Y | N | Y | Y | Y | N | N | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 3 | Rehder (2012) | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 4 | Bauer (2011) | Y | Y | N | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | N | Y | Y | Y | Y |
| 5 | Ceresoli (2010) | Y | Y | N | Y | Y | Y | Y | N | Y | Y | N | Y | Y | N | Y | Y | Y | N |
| 6 | Cornel (2010) | Y | Y | Y | Y | N | Y | Y | N | Y | Y | Y | Y | Y | Y | Y | N | Y | Y |
| 7 | Cornu (2010) | Y | Y | N | N | Y | Y | Y | N | Y | Y | Y | N | Y | N | Y | Y | Y | N |
| 8 | Soljanik (2010) | Y | Y | N | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 9 | Wadie (2010) | Y | Y | N | Y | N | Y | Y | N | Y | Y | Y | N | Y | Y | Y | Y | Y | Y |
| 10 | Bauer (2009) | Y | Y | N | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 11 | Grise (2009) | Y | Y | Y | Y | N | Y | Y | N | Y | Y | Y | Y | Y | N | Y | N | Y | Y |
| 12 | Guimarães (2009) | Y | Y | N | Y | N | Y | Y | N | Y | Y | N | Y | Y | Y | Y | Y | Y | N |
| 13 | Gilling (2008) | Y | Y | N | Y | N | Y | Y | N | N | N | Y | NA | Y | Y | Y | Y | Y | N |
| 14 | Inci (2008) | Y | Y | N | N | Y | Y | Y | N | Y | Y | Y | Y | Y | N | Y | Y | Y | N |
| 15 | Fischer (2007) | Y | Y | N | Y | N | Y | Y | N | Y | Y | Y | Y | Y | N | Y | Y | Y | Y |
| 16 | Gallagher (2007) | Y | Y | N | N | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | Y | Y | Y | N |
| 17 | Rehder (2007) | Y | Y | N | Y | N | Y | Y | N | Y | Y | Y | NA | Y | N | Y | Y | Y | Y |
| 18 | Sousa-Escando´n (2007) | Y | Y | Y | Y | N | Y | Y | N | Y | Y | Y | NA | Y | N | Y | Y | Y | N |
| 19 | Wadie (2007) | Y | Y | N | N | N | Y | Y | N | N | Y | N | NA | Y | N | Y | N | Y | N |
| 20 | Romano (2006) | Y | Y | Y | Y | N | Y | Y | N | Y | Y | Y | NA | Y | N | Y | Y | Y | Y |
| 21 | Stern (2005) | Y | Y | N | N | N | Y | Y | N | Y | Y | Y | NA | Y | Y | Y | N | Y | Y |
| 22 | John (2004) | Y | Y | Y | N | Y | Y | Y | N | Y | Y | Y | NA | Y | N | Y | N | Y | N |
| 23 | Schaal (2004) | Y | Y | N | Y | N | Y | Y | N | N | N | N | NA | Y | N | Y | N | Y | N |
| 24 | Comiter (2002) | Y | Y | N | N | N | Y | Y | N | Y | Y | Y | NA | Y | N | Y | Y | N | Y |
| 25 | Madjar (2001) | Y | Y | N | N | N | Y | Y | N | Y | Y | Y | NA | Y | N | Y | N | Y | Y |
| 26 | Jorion (1997) | Y | Y | N | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | N | Y | Y | Y | N |
| 1 | Lai (2011) | Y | Y | N | Y | Y | Y | Y | N | N | NA | Y | Y | Y | N | Y | N | Y | Y |
| 2 | Hübner (2007) | Y | Y | N | Y | N | Y | Y | N | Y | Y | Y | Y | Y | N | Y | Y | Y | N |
| 3 | Kocjancic (2007) | Y | Y | N | Y | N | Y | Y | N | Y | Y | Y | Y | Y | N | Y | Y | Y | N |
| 4 | Trigo-Rocha (2006) | Y | Y | N | Y | N | Y | Y | N | Y | Y | Y | Y | Y | N | Y | Y | Y | N |
| 5 | Imamoglu (2005) | Y | Y | N | Y | N | Y | Y | N | Y | Y | Y | N | Y | N | Y | Y | Y | N |
| 6 | Kuznetsov (2000) | Y | Y | N | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | N | Y | Y | Y | N |
| 7 | Mottet (1998) | N | Y | Y | Y | N | Y | Y | N | Y | Y | Y | Y | Y | N | Y | Y | Y | N |
| 8 | Litwiller (1996) | Y | Y | N | Y | N | Y | Y | N | Y | Y | Y | Y | Y | N | Y | Y | Y | N |
Y: yes; N: No; NA: not available.
Fig 2Meta-analysis for daily pad amount for patients treated with sling (A) and AUS (B).
Fig 3Meta-analysis for cured rate for patients treated with sling (A) and AUS (B).
Fig 4Meta-analysis for improve rate for patients treated with sling (A) and AUS (B).
Fig 5Meta-analysis for QOL score for patients treated with sling (A) and AUS (B).
Fig 6Sensitivity -analysis for daily pad amount for patients treated with sling (A) and AUS (B).
Fig 7Funnel plot for publication bias for daily pad amount for patients treated with sling.